These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7805084)

  • 1. Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty.
    Barry WL; Sarembock IJ
    Cardiol Clin; 1994 Aug; 12(3):517-35. PubMed ID: 7805084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
    Schächinger V; Zeiher AM
    Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for percutaneous coronary interventions.
    Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal antithrombotic treatment for percutaneous coronary intervention.
    Kadakia RA; Ferguson JJ
    Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-thrombotic and anticoagulant treatment in interventional cardiology.
    Mahanonda N
    J Med Assoc Thai; 1998 Jan; 81(1):42-6. PubMed ID: 9470321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
    Meyer BJ
    Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    May AE; Geisler T; Gawaz M
    Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
    Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
    Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
    Tcheng JE
    J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):100-12. PubMed ID: 20926950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
    Wheeldon N; Cumberland D
    Cathet Cardiovasc Diagn; 1997 Nov; 42(3):249-56. PubMed ID: 9367094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New antithrombotic agents in coronary disease].
    Montalescot G
    Rev Med Interne; 1997; 18(6):450-9. PubMed ID: 9247044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification.
    Patti G; Di Sciascio G
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):128-34. PubMed ID: 19670304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
    Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
    Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.